Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID - Characterizing Long COVID Phenotypes Using Physiological and Molecular Studies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Columbia University
- Locations
- 1
- Primary Endpoint
- Prevalence of Microvascular dysfunction
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function.
AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID.
Detailed Description
As many as 40-60% of patients who recovered from mild or moderate acute COVID have reported what is now called long COVID - multiple, persistent or recurrent symptoms lasting 6-9 months (or longer) following initial illness.1-4 Fatigue, dyspnea, and chest pain are the most common symptoms. Others include palpitations, lightheadedness, and syncope. All these cardiovascular symptoms can be debilitating, resulting in worse quality of life and morbidity.5, 6 Treatment options are limited.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18, \< 75 yrs
- •History of lab-confirmed COVID
- •Symptomatic at \>12 wks post-acute COVID (cases)
- •Recovered by 8wks post-acute COVID (controls)
Exclusion Criteria
- •Any history of critical illness
- •Chronic kidney disease, Stage \>4
- •Pre-COVID: HFrEF, CABG, arrhythmia; pulmonary hypertension, pulmonary embolus, interstitial lung disease (ILD), O2 dependence; dementia, stroke, autonomic dysfunction; coagulopathy
- •Post-COVID: ILD, O2 dependence
Outcomes
Primary Outcomes
Prevalence of Microvascular dysfunction
Time Frame: Up to 2.5 years
This is to measure the microvascular dysfunction in patients using Cardiac PET.